Skip to content

A study in patients with uncontrolled, non insulin dependent (NIDDM) diabetes mellitus (Type 2).

An Exploratory, Open-Label, Add-On study to evaluate the safety and efficacy of PB-DM-04 in patients with uncontrolled, non insulin dependent (NIDDM) diabetes mellitus (Type 2).

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/11/002170
Enrollment
50
Registered
2011-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type II Diabetes Mellitus

Interventions

Intervention1: PB-DM-04: Each Capsule contains: Methi: 110 mg Amla: 90 mg Grape: 80 mg Curcuma: 70 mg Dosage: 2 capsules per day (one in the morning and one in the evening before meals) together wit

Sponsors

Plantachem GbR
Lead Sponsor
Vedic Lifesciences Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: • Diagnosed with Non insulin dependent diabetes mellitus (NIDDM) type 2, under treatment since at least 1 year • Uncontrolled diabetes type 2 • On a stable dose of metformin and/or sulfonylurea since at least 6 months before recruitment without showing any improvement • Fasting blood sugar >= 145 mg/dl but = 200 mg/dl but • HbA1C >= 7.5 % but • Patients who have been following a steady lifestyle (in terms of diet and exercise for the last 3 months) and are willing to continue the same without any changes during the study period

Exclusion criteria

Exclusion criteria: • On herbal product(s) for any condition • On any other OHA besides metformin and sulfonylurea • On insulin • Taking hypolipidemic drugs • On any drug (besides that prescribed for glycaemic control) that is known to affect blood sugar levels • Hepatic impairment • Presence of major systemic disorders • Known cases of renal impairment or cardiac disorders • Women who are pregnant / lactating/ unwilling to adopt suitable methods of contraception during the study period and for up to 3 months after study completion.

Design outcomes

Primary

MeasureTime frame
- FBS - PPBS - HbA1c - Lipid Profile - BMI Timepoint: FBS - Day -5, Day 21, Day 42, Day 63 and Day 84 PPBS - Day -5, Day 42 and Day 84 HbA1c - Day -5, Day 42 and Day 84 Lipid Profile - Day -5, Day 42 and Day 84 BMI - Day 0, Day 21, Day 42, Day 63 and Day 84

Secondary

MeasureTime frame
NoneTimepoint: Not Applicable

Countries

India

Contacts

Public ContactSeema Damakale

Vedic Lifesciences Pvt. Ltd.

pratiksha.n@vediclifesciences.com022-42025705

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026